The information in this preliminary pricing
supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to
buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to completion dated August 6,
2024
Pricing supplement
To prospectus dated April 13, 2023,
prospectus supplement dated April 13, 2023,
product supplement no. 4-I dated April 13, 2023 and
prospectus addendum dated June 3, 2024 |
Registration Statement Nos. 333-270004 and 333-270004-01
Dated August , 2024
Rule 424(b)(2)
|
| JPMorgan Chase Financial Company LLC |
|
Structured
Investments |
$
Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. due August 21, 2025
Fully and Unconditionally Guaranteed by JPMorgan Chase & Co. |
General
| · | The notes are designed for investors who seek a fixed return
of at least 19.00% if the Final Stock Price is greater than or equal to the Stock Strike Price or is less than the Initial Stock Price
by up to 10.00%. |
| · | Investors should be willing to forgo interest and dividend
payments and, if the Final Stock Price is less than the Stock Strike Price by more than 10.00%, be willing to lose some or all of their
principal amount at maturity. |
| · | The notes are unsecured and unsubordinated obligations of
JPMorgan Chase Financial Company LLC, which we refer to as JPMorgan Financial, the payment on which is fully and unconditionally guaranteed
by JPMorgan Chase & Co. Any payment on the notes is subject to the credit risk of JPMorgan Financial, as issuer of the
notes, and the credit risk of JPMorgan Chase & Co., as guarantor of the notes. |
| · | Minimum denominations of $10,000 and integral multiples of
$1,000 in excess thereof |
Key Terms
| Issuer: |
JPMorgan Chase Financial Company LLC, an indirect, wholly owned finance subsidiary of JPMorgan Chase & Co. |
| Guarantor: |
JPMorgan Chase & Co. |
| Reference Stock: |
The common stock of Pfizer Inc., par value $0.05 per share (Bloomberg ticker: PFE UN). We refer to Pfizer Inc. as “Pfizer.” |
Payment at Maturity:
|
If the Final Stock Price is greater than or equal to the Stock Strike Price or is less than the Stock Strike Price by up to the Contingent Buffer Amount, at maturity you will receive a cash payment that provides you with a return per $1,000 principal amount note equal to the Contingent Digital Return. Accordingly, under these circumstances, your payment at maturity per $1,000 principal amount note will be calculated as follows: |
| |
$1,000 + ($1,000 × Contingent Digital Return) |
| |
If the Final Stock Price is less than the Stock Strike Price by more than
the Contingent Buffer Amount, at maturity you will lose 1% of the principal amount of your notes for every 1% that the Final Stock Price
is less than the Stock Strike Price. Under these circumstances, your payment at maturity per $1,000 principal amount note will be calculated
as follows:
$1,000 + ($1,000 × Stock Return)
If the Final Stock Price is less than the Stock Strike Price by more than
the Contingent Buffer Amount of 10.00%, you will lose more than 10.00% of your principal amount at maturity and may lose all of your principal
amount at maturity. |
| Contingent Digital Return: |
At least 19.00%*, which reflects the maximum return on the notes. Accordingly,
the maximum payment at maturity per $1,000 principal amount note is $1,190.00.
*The actual maximum payment at maturity will be provided in the pricing
supplement and will not be less than $1,190.00 per $1,000 principal amount note. |
| Contingent Buffer Amount: |
10.00% |
| Stock Return: |
(Final Stock Price – Stock Strike
Price)
Stock Strike Price |
| Stock Strike Price: |
$29.74, which was the closing price of one share of the Reference Stock on the Strike Date. The Stock Strike Price is not determined by reference to the closing price of the Reference Stock on the Pricing Date. |
| Final Stock Price: |
The closing price of one share of the Reference Stock on the Valuation Date |
| Stock Adjustment Factor: |
The Stock Adjustment Factor is referenced in determining the closing price of one share of the Reference Stock and is set initially at 1.0 on the Strike Date. The Stock Adjustment Factor is subject to adjustment upon the occurrence of certain corporate events affecting the Reference Stock. See “The Underlyings — Reference Stocks — Anti-Dilution Adjustments” and “The Underlyings — Reference Stocks — Reorganization Events” in the accompanying product supplement for further information. |
| Strike Date: |
August 5, 2024 |
| Pricing Date: |
On or about August 6, 2024 |
| Original Issue Date (Settlement Date): |
On or about August 9, 2024 |
| Valuation Date*: |
August 18, 2025 |
| Maturity Date*: |
August 21, 2025 |
| CUSIP: |
48135TAL7 |
| * | Subject to postponement in the event of a market disruption event and as described under “General Terms of Notes — Postponement
of a Determination Date — Notes Linked to a Single Underlying — Notes Linked to a Single Underlying (Other Than a Commodity
Index)” and “General Terms of Notes — Postponement of a Payment Date” in the accompanying product supplement |
Investing in the notes involves a number of risks. See “Risk
Factors” beginning on page S-2 of the accompanying prospectus supplement, Annex A to the accompanying prospectus addendum, “Risk
Factors” beginning on page PS-11 of the accompanying product supplement and “Selected Risk Considerations” beginning
on page PS-5 of this pricing supplement.
Neither the Securities and Exchange Commission (the “SEC”)
nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this pricing
supplement or the accompanying product supplement, prospectus supplement, prospectus and prospectus addendum. Any representation to the
contrary is a criminal offense.
| |
Price to Public (1) |
Fees and Commissions (2) |
Proceeds to Issuer |
| Per note |
$1,000 |
$ |
$ |
| Total |
$ |
$ |
$ |
| (1) | See “Supplemental Use of Proceeds” in this pricing supplement for information about the components of the price to public
of the notes. |
| (2) | J.P. Morgan Securities LLC, which we refer to as JPMS, acting as agent for JPMorgan Financial, will pay all of the selling commissions
it receives from us to other affiliated or unaffiliated dealers. In no event will these selling commissions exceed $5.00 per $1,000 principal
amount note. See “Plan of Distribution (Conflicts of Interest)” in the accompanying product supplement. |
If the notes priced today, the estimated value of the notes would
be approximately $969.80 per $1,000 principal amount note. The estimated value of the notes, when the terms of the notes are set, will
be provided in the pricing supplement and will not be less than $950.00 per $1,000 principal amount note. See “The Estimated
Value of the Notes” in this pricing supplement for additional information.
The notes are not bank deposits, are not insured by the Federal
Deposit Insurance Corporation or any other governmental agency and are not obligations of, or guaranteed by, a bank.
Additional Terms Specific to the
Notes
You may revoke your offer to purchase the notes at
any time prior to the time at which we accept such offer by notifying the applicable agent. We reserve the right to change the terms of,
or reject any offer to purchase, the notes prior to their issuance. In the event of any changes to the terms of the notes, we will notify
you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes, in which
case we may reject your offer to purchase.
You should read this pricing supplement together with
the accompanying prospectus, as supplemented by the accompanying prospectus supplement relating to our Series A medium-term notes of which
these notes are a part, the accompanying prospectus addendum and the more detailed information contained in the accompanying product supplement.
This pricing supplement, together with the documents listed below, contains the terms of the notes and supersedes all other prior or
contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms, correspondence,
trade ideas, structures for implementation, sample structures, fact sheets, brochures or other educational materials of ours. You
should carefully consider, among other things, the matters set forth in the “Risk Factors” sections of the accompanying prospectus
supplement and the accompanying product supplement and in Annex A to the accompanying prospectus addendum, as the notes involve risks
not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisers before
you invest in the notes.
You may access these documents on the SEC website at
www.sec.gov as follows (or if such address has changed, by reviewing our filings for the relevant date on the SEC website):
Our Central Index Key, or CIK, on the SEC website is
1665650, and JPMorgan Chase & Co.’s CIK is 19617. As used in this pricing supplement, “we,” “us”
and “our” refer to JPMorgan Financial.
| JPMorgan Structured Investments — | PS- 1 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
What Is the Total Return on the
Notes at Maturity, Assuming a Range of Performances for the Reference Stock?
The following table and examples illustrate the hypothetical
total return and the hypothetical payment at maturity on the notes. The “total return” as used in this pricing supplement
is the number, expressed as a percentage, that results from comparing the payment at maturity per $1,000 principal amount note to $1,000.
Each hypothetical total return or payment at maturity set forth below assumes a hypothetical Stock Strike Price of $100 and a Contingent
Digital Return of at least 19.00%, and reflects the Contingent Buffer Amount of 10.00%. The hypothetical Stock Strike Price of $100.00
has been chosen for illustrative purposes only and does not represent the actual Stock Strike Price. The actual maximum payment at maturity
will be provided in the pricing supplement and will not be less than $1,190.00 per $1,000 principal amount note. Each hypothetical total
return or payment at maturity set forth below is for illustrative purposes only and may not be the actual total return or payment at maturity
applicable to a purchaser of the notes. The numbers appearing in the following table and in the examples below have been rounded for ease
of analysis.
Final Stock
Price |
Stock Return |
Total Return |
| $180.00 |
80.00% |
19.00% |
| $170.00 |
70.00% |
19.00% |
| $160.00 |
60.00% |
19.00% |
| $150.00 |
50.00% |
19.00% |
| $140.00 |
40.00% |
19.00% |
| $130.00 |
30.00% |
19.00% |
| $120.00 |
20.00% |
19.00% |
| $119.00 |
19.00% |
19.00% |
| $110.00 |
10.00% |
19.00% |
| $105.00 |
5.00% |
19.00% |
| $102.50 |
2.50% |
19.00% |
| $100.00 |
0.00% |
19.00% |
| $97.50 |
-2.50% |
19.00% |
| $95.00 |
-5.00% |
19.00% |
| $90.00 |
-10.00% |
19.00% |
| $89.99 |
-10.01% |
-10.01% |
| $80.00 |
-20.00% |
-20.00% |
| $70.00 |
-30.00% |
-30.00% |
| $60.00 |
-40.00% |
-40.00% |
| $50.00 |
-50.00% |
-50.00% |
| $40.00 |
-60.00% |
-60.00% |
| $30.00 |
-70.00% |
-70.00% |
| $20.00 |
-80.00% |
-80.00% |
| $10.00 |
-90.00% |
-90.00% |
| $0.00 |
-100.00% |
-100.00% |
| JPMorgan Structured Investments — | PS- 2 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
Hypothetical Examples of Amount
Payable at Maturity
The following examples illustrate how the total payment
at maturity in different hypothetical scenarios is calculated.
Example 1: The price of one share of the Reference
Stock increases from the Stock Strike Price of $100.00 to a Final Stock Price of $102.50.
Because the Final Stock Price of $102.50 is greater
than the Stock Strike Price of $100.00, regardless of the Stock Return, the investor receives a payment at maturity of $190.00 per $1,000
principal amount note, calculated as follows:
$1,000 + ($1,000 × 19.00%)
= $1,190.00
Example 2: The price of one share of the Reference
Stock decreases from the Stock Strike Price of $100.00 to a Final Stock Price of $90.00.
Although the Reference Stock has depreciated, because
the Final Stock Price of $90.00 is less than the Stock Strike Price of $100.00 by up to the Contingent Buffer Amount of 10.00%, the investor
receives a payment at maturity of $1,190.00 per $1,000 principal amount note, calculated as follows:
$1,000 + ($1,000 × 19.00%)
= $1,190.00
Example 3: The price of one share of the Reference
Stock increases from the Stock Strike Price of $100.00 to a Final Stock Price of $160.00.
Because the Final Stock Price of $160.00 is greater
than the Stock Strike Price of $100.00 and although the Stock Return of 60.00% exceeds the Contingent Digital Return of 19.00%, the investor
is entitled to only the Contingent Digital Return and receives a payment at maturity of $1,190.00 per $1,000 principal amount note, calculated
as follows:
$1,000 + ($1,000 × 19.00%)
= $1,190.00
Example 4: The closing price of one share of the
Reference Stock decreases from the Stock Strike Price of $100.00 to a Final Stock Price of $40.00.
Because the Final Stock Price of $40.00 is less than
the Stock Strike Price of $100.00 by more than the Contingent Buffer Amount of 10.00% and the Stock Return is -60.00%, the investor receives
a payment at maturity of $400.00 per $1,000 principal amount note, calculated as follows:
$1,000 + ($1,000 × -60.00%)
= $400.00
The hypothetical returns and hypothetical payments on
the notes shown above apply only if you hold the notes for their entire term. These hypotheticals do not reflect fees or expenses
that would be associated with any sale in the secondary market. If these fees and expenses were included, the hypothetical returns and
hypothetical payments shown above would likely be lower.
| JPMorgan Structured Investments — | PS- 3 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
Selected Purchase Considerations
| · | FIXED APPRECIATION POTENTIAL
— If the Final Stock Price is greater than or equal to the Stock Strike Price or is less than the Stock Strike Price by up to the
Contingent Buffer Amount, you will receive a fixed return equal to the Contingent Digital Return of at least 19.00% at maturity, which
also reflects the maximum return on the notes at maturity. The actual maximum payment at maturity will be provided in the pricing supplement
and will not be less than $1,190.00 per $1,000 principal amount note. Because the notes are our unsecured and unsubordinated obligations,
the payment of which is fully and unconditionally guaranteed by JPMorgan Chase & Co., payment of any amount on the notes
is subject to our ability to pay our obligations as they become due and JPMorgan Chase & Co.’s ability to pay its
obligations as they become due. |
| · | LOSS OF PRINCIPAL BEYOND
THE CONTINGENT BUFFER AMOUNT — We will pay you the Contingent Digital Return of at least 19.00% at maturity if the Final Stock
Price is greater than or equal to the Stock Strike Price or is less than the Stock Strike Price by up to the Contingent Buffer Amount
of 10.00%. If the Final Stock Price is less than the Stock Strike Price by more than the Contingent Buffer Amount, for every 1% that the
Final Stock Price is less than the Stock Strike Price, you will lose an amount equal to 1% of the principal amount of your notes. Under
these circumstances, you will lose more than 10.00% of your principal amount at maturity and may lose all of your principal amount at
maturity. |
| · | RETURN DEPENDENT ON A
SINGLE REFERENCE STOCK — The return on the notes is linked to the performance of a single Reference Stock, which is the common
stock of Pfizer. For additional information see “The Reference Stock” in this pricing supplement. |
| · | TAX TREATMENT —
You should review carefully the section entitled “Material U.S. Federal Income Tax Consequences” in the accompanying product
supplement no. 4-I. The following discussion, when read in combination with that section, constitutes the full opinion of our special
tax counsel, Latham & Watkins LLP, regarding the material U.S. federal income tax consequences of owning and disposing of notes. |
Based on current market conditions,
in the opinion of our special tax counsel it is reasonable to treat the notes as “open transactions” that are not debt instruments
for U.S. federal income tax purposes, as more fully described in “Material U.S. Federal Income Tax Consequences — Tax Consequences
to U.S. Holders — Notes Treated as Open Transactions That Are Not Debt Instruments” in the accompanying product supplement.
Assuming this treatment is respected, the gain or loss on your notes should be treated as long-term capital gain or loss if you hold your
notes for more than a year, whether or not you are an initial purchaser of notes at the issue price. However, the IRS or a court may not
respect this treatment, in which case the timing and character of any income or loss on the notes could be materially and adversely affected.
In addition, in 2007 Treasury and the IRS released a notice requesting comments on the U.S. federal income tax treatment of “prepaid
forward contracts” and similar instruments. The notice focuses in particular on whether to require investors in these instruments
to accrue income over the term of their investment. It also asks for comments on a number of related topics, including the character of
income or loss with respect to these instruments; the relevance of factors such as the nature of the underlying property to which the
instruments are linked; the degree, if any, to which income (including any mandated accruals) realized by non-U.S. investors should be
subject to withholding tax; and whether these instruments are or should be subject to the “constructive ownership” regime,
which very generally can operate to recharacterize certain long-term capital gain as ordinary income and impose a notional interest charge.
While the notice requests comments on appropriate transition rules and effective dates, any Treasury regulations or other guidance promulgated
after consideration of these issues could materially and adversely affect the tax consequences of an investment in the notes, possibly
with retroactive effect. You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the
notes, including possible alternative treatments and the issues presented by this notice.
Section 871(m) of the Code and Treasury
regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding tax (unless an income tax treaty
applies) on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S.
equities or indices that include U.S. equities. Section 871(m) provides certain exceptions to this withholding regime, including for instruments
linked to certain broad-based indices that meet requirements set forth in the applicable Treasury regulations (such an index, a “Qualified
Index”). Additionally, a recent IRS notice excludes from the scope of Section 871(m) instruments issued prior to January 1, 2027
that do not have a delta of one with respect to underlying securities that could pay U.S.-source dividends for U.S. federal income tax
purposes (each an “Underlying Security”). Based on certain determinations made by us, we expect that Section 871(m) will not
apply to the notes with regard to Non-U.S. Holders. Our determination is not binding on the IRS, and the IRS may disagree with this determination.
Section 871(m) is complex and its application may depend on your particular circumstances, including whether you enter into other transactions
with respect to an Underlying Security. If necessary, further information regarding the potential application of Section 871(m) will be
provided in the pricing supplement for the notes. You should consult your tax adviser regarding the potential application of Section 871(m)
to the notes.
Withholding under legislation commonly
referred to as “FATCA” may (if the notes are recharacterized as debt instruments) apply to amounts treated as interest paid
with respect to the notes, as well as to payments of gross proceeds of a taxable disposition, including redemption at maturity, of a note,
although under recently proposed regulations (the preamble to which specifies that taxpayers are permitted to rely on them pending finalization),
no
| JPMorgan Structured Investments — | PS- 4 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
withholding will apply to payments of gross proceeds
(other than any amount treated as interest). You should consult your tax adviser regarding the potential application of FATCA to the notes.
Selected Risk Considerations
An investment in the notes involves significant risks.
Investing in the notes is not equivalent to investing directly in the Reference Stock. These risks are explained in more detail in the
“Risk Factors” sections of the accompanying prospectus supplement and product supplement and in Annex A to the accompanying
prospectus addendum.
Risks Relating to the Notes Generally
| · | YOUR
INVESTMENT IN THE NOTES MAY RESULT IN A LOSS — The notes do not guarantee any return of principal. The return on the notes
at maturity is dependent on the performance of the Reference Stock and will depend on whether, and the extent to which, the Final Stock
Price is less than the Stock Strike Price. Your investment will be exposed to a loss if the Final Stock Price is less than the Stock
Strike Price by more than the Contingent Buffer Amount. In this case, for every 1% that the Final Stock Price is less than the Stock
Strike Price, you will lose an amount equal to 1% of the principal amount of your notes. Under these circumstances, you will lose more
than 10.00% of your principal amount at maturity and may lose all of your principal amount at maturity. |
| · | YOUR
MAXIMUM GAIN ON THE NOTES IS LIMITED TO THE CONTINGENT DIGITAL RETURN — If the Final Stock Price is greater than or equal to
the Stock Strike Price or is less than the Stock Strike Price by up to the Contingent Buffer Amount, for each $1,000 principal amount
note, you will receive at maturity $1,000 plus an additional return equal to the Contingent Digital Return of at least 19.00%,
regardless of any appreciation of the Reference Stock, which may be significant. |
| · | YOUR ABILITY TO RECEIVE
THE CONTINGENT DIGITAL RETURN MAY TERMINATE ON THE VALUATION DATE — If the Final Stock Price is less than the Stock Strike Price
by more than the Contingent Buffer Amount, you will not be entitled to receive the Contingent Digital Return at maturity. Under these
circumstances, you will lose more than 10.00% of your principal amount at maturity and may lose all of your principal amount at maturity. |
| · | THE BENEFIT PROVIDED BY
THE CONTINGENT BUFFER AMOUNT MAY TERMINATE ON THE VALUATION DATE — If the Final Stock Price is less than the Stock Strike Price
by more than the Contingent Buffer Amount, the benefit provided by the Contingent Buffer Amount will terminate and you will be fully exposed
to any depreciation of the Reference Stock from the Stock Strike Price to the Final Stock Price. |
| · | CREDIT
RISKS OF JPMORGAN FINANCIAL AND JPMORGAN CHASE & CO. — The notes are subject to our and JPMorgan Chase & Co.’s
credit risks, and our and JPMorgan Chase & Co.’s credit ratings and credit spreads may adversely affect the market
value of the notes. Investors are dependent on our and JPMorgan Chase & Co.’s ability to pay all amounts due
on the notes. Any actual or potential change in our or JPMorgan Chase & Co.’s creditworthiness or credit spreads,
as determined by the market for taking that credit risk, is likely to adversely affect the value of the notes. If we and JPMorgan
Chase & Co. were to default on our payment obligations, you may not receive any amounts owed to you under the notes and
you could lose your entire investment. |
| · | AS A FINANCE SUBSIDIARY,
JPMORGAN FINANCIAL HAS NO INDEPENDENT OPERATIONS AND HAS LIMITED ASSETS — As a finance subsidiary of JPMorgan Chase & Co.,
we have no independent operations beyond the issuance and administration of our securities and the collection of intercompany obligations.
Aside from the initial capital contribution from JPMorgan Chase & Co., substantially all of our assets relate to obligations
of JPMorgan Chase & Co. to make payments under loans made by us to JPMorgan Chase & Co. or under other intercompany
agreements. As a result, we are dependent upon payments from JPMorgan Chase & Co. to meet our obligations under the notes.
We are not a key operating subsidiary of JPMorgan Chase & Co. and in a bankruptcy or resolution of JPMorgan Chase & Co.
we are not expected to have sufficient resources to meet our obligations in respect of the notes as they come due. If JPMorgan Chase & Co.
does not make payments to us and we are unable to make payments on the notes, you may have to seek payment under the related guarantee
by JPMorgan Chase & Co., and that guarantee will rank pari passu with all other unsecured and unsubordinated obligations
of JPMorgan Chase & Co. For more information, see the accompanying prospectus addendum. |
| · | NO OWNERSHIP OR DIVIDEND
RIGHTS IN THE REFERENCE STOCK — As a holder of the notes, you will not have any ownership interest or rights in the Reference
Stock, such as voting rights or dividend payments. In addition, the issuer of the Reference Stock will not have any obligation to consider
your interests as a holder of the notes in taking any corporate action that might affect the value of the Reference Stock and the notes. |
| · | SINGLE STOCK RISK —
The price of the Reference Stock can fall sharply due to factors specific to the Reference Stock and its issuer, such as stock price volatility,
earnings, financial conditions, corporate, industry and regulatory developments, management changes and decisions and other events, as
well as general market factors, such as general stock market volatility and levels, interest rates and economic and political conditions. |
| · | NO
INTEREST PAYMENTS — As a holder of the notes, you will not receive any interest payments. |
| · | VOLATILITY RISK —
Greater expected volatility with respect to the Reference Stock indicates a greater likelihood as of the Strike Date and the Pricing Date
that the Final Stock Price could be less than the Stock Strike |
| JPMorgan Structured Investments — | PS- 5 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
Price by more than the Contingent Buffer Amount. The
Reference Stock’s volatility, however, can change significantly over the term of the notes. The closing price of one share of the
Reference Stock could fall sharply during the term of the notes, which could result in your losing some or all of your principal amount
at maturity.
| · | LACK OF LIQUIDITY
— The notes will not be listed on any securities exchange. JPMS intends to offer to purchase the notes in the secondary market but
is not required to do so. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the notes
easily. Because other dealers are not likely to make a secondary market for the notes, the price at which you may be able to trade your
notes is likely to depend on the price, if any, at which JPMS is willing to buy the notes. |
| · | THE FINAL TERMS AND VALUATION
OF THE NOTES WILL BE PROVIDED IN THE PRICING SUPPLEMENT — The final terms of the notes will be based on relevant market conditions
when the terms of the notes are set and will be provided in the pricing supplement. In particular, the estimated value of the notes will
be provided in the pricing supplement and may be as low as the minimum for the estimated value of the notes set forth on the cover of
this pricing supplement. Accordingly, you should consider your potential investment in the notes based on the minimum for the estimated
value of the notes. |
Risks Relating
to Conflicts of Interest
| · | POTENTIAL CONFLICTS
— We and our affiliates play a variety of roles in connection with the issuance of the notes, including acting as calculation agent
and as an agent of the offering of the notes, hedging our obligations under the notes and making the assumptions used to determine the
pricing of the notes and the estimated value of the notes when the terms of the notes are set, which we refer to as the estimated value
of the notes. In performing these duties, our and JPMorgan Chase & Co.’s economic interests and the economic interests
of the calculation agent and other affiliates of ours are potentially adverse to your interests as an investor in the notes. In addition,
our and JPMorgan Chase & Co.’s business activities, including hedging and trading activities, could cause our and
JPMorgan Chase & Co.’s economic interests to be adverse to yours and could adversely affect any payment on the notes
and the value of the notes. It is possible that hedging or trading activities of ours or our affiliates in connection with the notes could
result in substantial returns for us or our affiliates while the value of the notes declines. Please refer to “Risk Factors —
Risks Relating to Conflicts of Interest” in the accompanying product supplement for additional information about these risks. |
We and/or our affiliates may also
currently or from time to time engage in business with Pfizer, including extending loans to, or making equity investments in, Pfizer or
providing advisory services to Pfizer. In addition, one or more of our affiliates may publish research reports or otherwise express opinions
with respect to Pfizer, and these reports may or may not recommend that investors buy or hold the Reference Stock. As a prospective purchaser
of the notes, you should undertake an independent investigation of the Reference Stock issuer that in your judgment is appropriate to
make an informed decision with respect to an investment in the notes.
Risks Relating
to the Estimated Value and Secondary Market Prices of the Notes
| · | THE ESTIMATED VALUE OF
THE NOTES WILL BE LOWER THAN THE ORIGINAL ISSUE PRICE (PRICE TO PUBLIC) OF THE NOTES — The estimated value of the notes is only
an estimate determined by reference to several factors. The original issue price of the notes will exceed the estimated value of the notes
because costs associated with selling, structuring and hedging the notes are included in the original issue price of the notes. These
costs include the selling commissions, the projected profits, if any, that our affiliates expect to realize for assuming risks inherent
in hedging our obligations under the notes and the estimated cost of hedging our obligations under the notes. See “The Estimated
Value of the Notes” in this pricing supplement. |
| · | THE ESTIMATED VALUE OF
THE NOTES DOES NOT REPRESENT FUTURE VALUES OF THE NOTES AND MAY DIFFER FROM OTHERS’ ESTIMATES — The estimated value of
the notes is determined by reference to internal pricing models of our affiliates when the terms of the notes are set. This estimated
value of the notes is based on market conditions and other relevant factors existing at that time and assumptions about market parameters,
which can include volatility, dividend rates, interest rates and other factors. Different pricing models and assumptions could provide
valuations for the notes that are greater than or less than the estimated value of the notes. In addition, market conditions and other
relevant factors in the future may change, and any assumptions may prove to be incorrect. On future dates, the value of the notes could
change significantly based on, among other things, changes in market conditions, our or JPMorgan Chase & Co.’s creditworthiness,
interest rate movements and other relevant factors, which may impact the price, if any, at which JPMS would be willing to buy notes from
you in secondary market transactions. See “The Estimated Value of the Notes” in this pricing supplement. |
| · | THE ESTIMATED VALUE OF
THE NOTES IS DERIVED BY REFERENCE TO AN INTERNAL FUNDING RATE — The internal funding rate used in the determination of the estimated
value of the notes may differ from the market-implied funding rate for vanilla fixed income instruments of a similar maturity issued by
JPMorgan Chase & Co. or its affiliates. Any difference may be based on, among other things, our and our affiliates’
view of the funding value of the notes as well as the higher issuance, operational and ongoing liability management costs of the notes
in comparison to those costs for the conventional fixed income instruments of JPMorgan Chase & Co. This internal funding
rate is based on certain market inputs and assumptions, which may prove to be incorrect, and is intended to approximate the prevailing
market replacement funding rate for the notes. The use of an |
| JPMorgan Structured Investments — | PS- 6 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
internal funding rate and any potential changes
to that rate may have an adverse effect on the terms of the notes and any secondary market prices of the notes. See “The Estimated
Value of the Notes” in this pricing supplement.
| · | THE VALUE OF THE NOTES
AS PUBLISHED BY JPMS (AND WHICH MAY BE REFLECTED ON CUSTOMER ACCOUNT STATEMENTS) MAY BE HIGHER THAN THE THEN-CURRENT ESTIMATED VALUE OF
THE NOTES FOR A LIMITED TIME PERIOD — We generally expect that some of the costs included in the original issue price of the
notes will be partially paid back to you in connection with any repurchases of your notes by JPMS in an amount that will decline to zero
over an initial predetermined period. These costs can include selling commissions, projected hedging profits, if any, and, in some circumstances,
estimated hedging costs and our internal secondary market funding rates for structured debt issuances. See “Secondary Market Prices
of the Notes” in this pricing supplement for additional information relating to this initial period. Accordingly, the estimated
value of your notes during this initial period may be lower than the value of the notes as published by JPMS (and which may be shown on
your customer account statements). |
| · | SECONDARY MARKET PRICES
OF THE NOTES WILL LIKELY BE LOWER THAN THE ORIGINAL ISSUE PRICE OF THE NOTES — Any secondary market prices of the notes will
likely be lower than the original issue price of the notes because, among other things, secondary market prices take into account our
internal secondary market funding rates for structured debt issuances and, also, because secondary market prices may exclude selling commissions,
projected hedging profits, if any, and estimated hedging costs that are included in the original issue price of the notes. As a result,
the price, if any, at which JPMS will be willing to buy notes from you in secondary market transactions, if at all, is likely to be lower
than the original issue price. Any sale by you prior to the Maturity Date could result in a substantial loss to you. See the immediately
following risk consideration for information about additional factors that will impact any secondary market prices of the notes. |
The notes are not designed to be
short-term trading instruments. Accordingly, you should be able and willing to hold your notes to maturity. See “— Lack of
Liquidity” below.
| · | SECONDARY MARKET PRICES
OF THE NOTES WILL BE IMPACTED BY MANY ECONOMIC AND MARKET FACTORS — The secondary market price of the notes during their term
will be impacted by a number of economic and market factors, which may either offset or magnify each other, aside from the selling commissions,
projected hedging profits, if any, estimated hedging costs and the price of one share of the Reference Stock. |
Additionally, independent pricing
vendors and/or third party broker-dealers may publish a price for the notes, which may also be reflected on customer account statements.
This price may be different (higher or lower) than the price of the notes, if any, at which JPMS may be willing to purchase your notes
in the secondary market. See “Risk Factors — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes
— Secondary market prices of the notes will be impacted by many economic and market factors” in the accompanying product supplement.
Risks Relating
to the Reference Stock
| · | NO AFFILIATION WITH THE
REFERENCE STOCK ISSUER — We are not affiliated with the issuer of the Reference Stock. We assume no responsibility for the adequacy
of the information about the Reference Stock issuer contained in this pricing supplement. You should undertake your own investigation
into the Reference Stock and its issuer. We are not responsible for the Reference Stock issuer’s public disclosure of information,
whether contained in SEC filings or otherwise. |
| · | THE ANTI-DILUTION PROTECTION
FOR THE REFERENCE STOCK IS LIMITED AND MAY BE DISCRETIONARY — The calculation agent will make adjustments to the Stock Adjustment
Factor for certain corporate events affecting the Reference Stock. However, the calculation agent will not make an adjustment in response
to all events that could affect the Reference Stock. If an event occurs that does not require the calculation agent to make an adjustment,
the value of the notes may be materially and adversely affected. You should also be aware that the calculation agent may make adjustments
in response to events that are not described in the accompanying product supplement to account for any diluting or concentrative effect,
but the calculation agent is under no obligation to do so or to consider your interests as a holder of the notes in making these determinations. |
| JPMorgan Structured Investments — | PS- 7 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
The Reference
Stock
Public Information
All information contained herein on the Reference
Stock and on Pfizer is derived from publicly available sources and is provided for informational purposes only. According to its publicly
available filings with the SEC, Pfizer is a research-based, global biopharmaceutical company. The common stock of Pfizer, par value $0.05
per share (Bloomberg ticker: PFE UN), is registered under the Securities Exchange Act of 1934, as amended, which we refer to as the “Exchange
Act”, and is listed on the New York Stock Exchange, which we refer to as the relevant exchange for purposes of Pfizer in the accompanying
product supplement. Information provided to or filed with the SEC by Pfizer pursuant to the Exchange Act can be located by reference to
SEC file number 001-3619, and can be accessed through www.sec.gov. We do not make any representation that these publicly available documents
are accurate or complete.
Historical Information Regarding
the Reference Stock
The following graph sets forth the historical performance
of the Reference Stock based on the weekly historical closing prices of one share of the Reference Stock from January 4, 2019 through
August 2, 2024. The closing price of one share of the Reference Stock on August 5, 2024 was $29.74. We obtained the closing prices above
and below from the Bloomberg Professional® service (“Bloomberg”), without independent verification. The closing
prices may have been adjusted by Bloomberg for corporate actions such as stock splits, public offerings, mergers and acquisitions, spin-offs,
delistings and bankruptcy.
Since its inception, the Reference
Stock has experienced significant fluctuations. The historical performance of the Reference Stock should not be taken as an indication
of future performance, and no assurance can be given as to the closing price of one share of the Reference Stock on the Pricing Date or
the Valuation Date. There can be no assurance that the performance of the Reference Stock will result in the return of any of your principal
amount.
The Estimated Value of the Notes
The estimated value of the notes set forth on the cover
of this pricing supplement is equal to the sum of the values of the following hypothetical components: (1) a fixed-income debt component
with the same maturity as the notes, valued using the internal funding rate described below, and (2) the derivative or derivatives underlying
the economic terms of the notes. The estimated value of the notes does not represent a minimum price at which JPMS would be willing to
buy your notes in any secondary market (if any exists) at any time. The internal funding rate used in the determination of the estimated
value of the notes may differ from the market-implied funding rate for vanilla fixed income instruments of a similar maturity issued by
JPMorgan Chase & Co. or its affiliates. Any difference may be based on, among other things, our and our affiliates’
view of the funding value of the notes as well as the higher issuance, operational and ongoing liability management costs of the notes
in comparison to those costs for the conventional fixed income instruments of JPMorgan Chase & Co. This internal funding
rate is based on certain market inputs and assumptions, which may prove to be incorrect, and is intended to approximate the prevailing
market replacement funding rate for the notes. The use of an internal funding rate and any potential changes to that rate may have an
adverse effect on the terms of the notes and any secondary market prices of the notes. For additional information, see “Selected
Risk Considerations — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes — The Estimated Value
of the Notes Is Derived by Reference to an Internal Funding Rate” in this pricing supplement. The value of the derivative or derivatives
underlying the economic terms of the notes is derived from internal pricing models of our affiliates. These models are dependent on inputs
such as the traded market prices of comparable derivative instruments and on various other inputs, some of which are market-observable,
and which can include volatility, dividend rates, interest rates and other factors, as well as
| JPMorgan Structured Investments — | PS- 8 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
assumptions about future market events and/or environments.
Accordingly, the estimated value of the notes is determined when the terms of the notes are set based on market conditions and other relevant
factors and assumptions existing at that time. See “Selected Risk Considerations — Risks Relating to the Estimated Value and
Secondary Market Prices of the Notes — The Estimated Value of the Notes Does Not Represent Future Values of the Notes and May Differ
from Others’ Estimates” in this pricing supplement.
The estimated value of the notes will be lower than
the original issue price of the notes because costs associated with selling, structuring and hedging the notes are included in the original
issue price of the notes. These costs include the selling commissions paid to JPMS and other affiliated or unaffiliated dealers, the projected
profits, if any, that our affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes and the
estimated cost of hedging our obligations under the notes. Because hedging our obligations entails risk and may be influenced by market
forces beyond our control, this hedging may result in a profit that is more or less than expected, or it may result in a loss. We or one
or more of our affiliates will retain any profits realized in hedging our obligations under the notes. See “Selected Risk Considerations
— Risks Relating to the Estimated Value and Secondary Market Prices of the Notes — The Estimated Value of the Notes Will Be
Lower Than the Original Issue Price (Price to Public) of the Notes” in this pricing supplement.
Secondary Market Prices of the Notes
For information about factors that will impact any secondary
market prices of the notes, see “Risk Factors — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes
— Secondary market prices of the notes will be impacted by many economic and market factors” in the accompanying product supplement.
In addition, we generally expect that some of the costs included in the original issue price of the notes will be partially paid back
to you in connection with any repurchases of your notes by JPMS in an amount that will decline to zero over an initial predetermined period.
These costs can include selling commissions, projected hedging profits, if any, and, in some circumstances, estimated hedging costs and
our internal secondary market funding rates for structured debt issuances. This initial predetermined time period is intended to be the
shorter of six months and one-half of the stated term of the notes. The length of any such initial period reflects the structure of the
notes, whether our affiliates expect to earn a profit in connection with our hedging activities, the estimated costs of hedging the notes
and when these costs are incurred, as determined by our affiliates. See “Selected Risk Considerations — Risks Relating to
the Estimated Value and Secondary Market Prices of the Notes — The Value of the Notes as Published by JPMS (and Which May Be Reflected
on Customer Account Statements) May Be Higher Than the Then-Current Estimated Value of the Notes for a Limited Time Period” in this
pricing supplement.
Supplemental Use of Proceeds
The notes are offered to meet investor demand for products
that reflect the risk-return profile and market exposure provided by the notes. See “What Is the Total Return on the Notes at Maturity,
Assuming a Range of Performances for the Reference Stock?” and “Hypothetical Examples of Amount Payable at Maturity”
in this pricing supplement for an illustration of the risk-return profile of the notes and “The Reference Stock” in this pricing
supplement for a description of the market exposure provided by the notes.
The original issue price of the notes is equal to the
estimated value of the notes plus the selling commissions paid to JPMS and other affiliated or unaffiliated dealers, plus (minus) the
projected profits (losses) that our affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes,
plus the estimated cost of hedging our obligations under the notes.
Supplemental Terms of the Notes
Any values of the Reference Stock, and any values derived
therefrom, included in this pricing supplement may be corrected, in the event of manifest error or inconsistency, by amendment of this
pricing supplement and the corresponding terms of the notes. Notwithstanding anything to the contrary in the indenture governing the notes,
that amendment will become effective without consent of the holders of the notes or any other party.
| JPMorgan Structured Investments — | PS- 9 |
| Digital Contingent Buffered Notes Linked to the Common Stock of Pfizer Inc. | |
JP Morgan Chase (NYSE:JPM-M)
Historical Stock Chart
From Oct 2024 to Nov 2024
JP Morgan Chase (NYSE:JPM-M)
Historical Stock Chart
From Nov 2023 to Nov 2024
